Table 2.
Molecular subtypes of prostate cancer bone metastases [98].
| Subtypes | N of Cases | Cellular Differentiation | Gene Expression | Ki-67 | PSA Level | Prognosis |
|---|---|---|---|---|---|---|
| MetA | 71% | Moderate cellular atypia, glandular differentiation | KLK3, FOXA1, KRT18, CDH1 | Low | High | Good |
| MetB | 17% | Prominent cellular atypia, lack of glandular differentiation | FOXM1, CCNB1-2, CDC25B, CDK1, PLK1, PKMYT1, LMB1, KNSL1, NCL, KRT18 and others | High | Low | Poor |
| MetC | 12% | Prominent cellular atypia, glandular differentiation detectable in some cases, relatively high stroma/epithelial ratio | ECM remodelling, regulation of EMT (Wnt, Notch, TGF-β, PDGF, immunological synapse formation, C/EBP, GSTP1 | Low | Low | Poor |